Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-0302 (ivarmacitinib) plus prednisone versus prednisone alone in active Takayasu arteritis
ChiCTR2500114756Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Takayasu arteritis (TAK) comparing SHR-0302 + glucocorticoids with Placebo + glucocorticoids (2 arms). Primary endpoint: Complete remission rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on ChiCTR2500114756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114756.